Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab in New Onset Type 1 Diabetes
NCT00737763Phase 2Withdrawn
- Sponsor
- Emory University
- Start
- Oct 2008
- Primary completion
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of efalizumab in type 1 diabetes mellitus (T1D), sponsored by Emory University. Planned start Oct 2008; status: withdrawn.
02
Drugs
efalizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00737763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00737763.